• Tue news: Obesity pill race heats up. Express Scripts sues FTC. More ESMO data. Kairos IPO. Daiichi-Merck guided-missile cancer drug. See more on our front page

Bristol Myers Squibb checks 'yes' on another Prothena neurodegenerative therapy

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 29, 2024 at 09:42: PM
via Bristol Myers Squibb is again dipping into the well of therapies being developed by Prothena, this time for an exclusive license to a neurodegenerative candidate that is about to slide into human testing.

article source
 




Similar threads

cafead
Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO
Replies
0
Views
20
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs
Replies
0
Views
51
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Bristol Myers Squibb closes immuno-oncology, cell therapy-focused Redwood City site
Replies
0
Views
118
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
Replies
0
Views
79
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote